• Alife Health, a technology company developing AI tools to improve fertility and reproductive health, has raised USD 22 million in a Series A round co-led by Deena Shakir (Lux Capital), Rebecca Kaden (Union Square Ventures), and Anarghya Vardhana (Maveron). This brings the total funds raised to over USD 31 million.

• The funds will be utilized to launch its two fertility products (Stim Assist and Alife mobile app) to the market and conduct clinical trials for its third fertility product (Embryo Predict), which is still in development.

• Stim Assist is an AI tool used during ovarian simulations—patients receive injected medications that stimulate the ovaries to produce and release mature eggs. This provides clinicians with insights that support their decision-making in utilizing the correct dose of medication to retrieve the maximum number of mature eggs per cycle from the patient for fertilization and implantation while reducing medication costs. Alife's mobile app is its first B2C platform, which it plans to launch later in 2022. The app will feature educational resources and tools for medication reminders, appointments, lab results, and more. Embryo Predict is an AI-based solution that helps embryologists in analyzing and transferring patient embryos.

<ul><li> Analyst QuickTake: The latest funding follows Alife Health’s USD 9.5 million seed funding round raised in May 2021, in which it used the funds to prepare its technology for regulatory review.</ul>